DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0090-9556/03/3108-1005-1015$20.00
DMD 31:1005-1015, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, L. H.
Right arrow Articles by Vaz, A. D. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, L. H.
Right arrow Articles by Vaz, A. D. N.

IN VITRO DRUG INTERACTIONS OF CYTOCHROME P450: AN EVALUATION OF FLUOROGENIC TO CONVENTIONAL SUBSTRATES

Lawrence H. Cohen, Michael J. Remley, David Raunig, and Alfin D. N. Vaz

Pfizer Global Research and Development, Groton, Connecticut

Clinically observed drug interactions with cytochrome P450 (P450) enzymes have increased the need to assess drug interactions of new chemical entities early in the discovery process. To meet this need, fluorogenic substrates have been commercialized. However, only limited evaluations of their utility and comparisons to drug probes have been reported. This study examines the correlation between IC50 values obtained with fluorogenic and conventional drug probes for structurally diverse inhibitors of the five major human P450 isoforms. In general, correlations are weak, with significant numbers of compounds being missed as inhibitors by either probe. For P450s 1A2, 2C9, and 2C19, correlation coefficients were above 0.6 with slopes that ranged from 1.5 to 4.2. However, for P450s 1A2 and 2C9, about 20% of compounds were not included because an IC50 value could not be determined with one of the two probes. CYP 2C19 had the highest correlation (correlation coefficient 0.84), with a slope of 2.0 and less than 5% of compounds excluded. CYP 2D6 showed a good correlation for IC50 values less than 10 µM. However, at higher IC50 values, a high degree of scatter was observed. CYP 3A4 had the weakest correlation, and a large number of compounds were excluded with the fluorogenic probe. Overall, the study shows the care needed when selecting fluorogenic probes and the caution needed when results with fluorogenic probes are used to drive structure-activity relationships with respect to drug interactions.

Address correspondence to: Lawrence H. Cohen, Candidate Enhancement Group, Pfizer Global Research and Development, Eastern Point Road, Groton CT 06340-5146. E-mail: larry_cohen{at}groton.pfizer.com




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
D. Aidasani, M. J. Zaya, P. B. Malpas, and C. W. Locuson
In Vitro Drug-Drug Interaction Screens for Canine Veterinary Medicines: Evaluation of Cytochrome P450 Reversible Inhibition
Drug Metab. Dispos., August 1, 2008; 36(8): 1512 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
L. Bell, S. Bickford, P. H. Nguyen, J. Wang, T. He, B. Zhang, Y. Friche, A. Zimmerlin, L. Urban, and D. Bojanic
Evaluation of Fluorescence- and Mass Spectrometry--Based CYP Inhibition Assays for Use in Drug Discovery
J Biomol Screen, June 1, 2008; 13(5): 343 - 353.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. Stadel, J. Yang, J. W. Nalwalk, J. G. Phillips, and L. B. Hough
High-Affinity Binding of [3H]Cimetidine to a Heme-Containing Protein in Rat Brain
Drug Metab. Dispos., March 1, 2008; 36(3): 614 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Di Marco, A. Cellucci, A. Chaudhary, M. Fonsi, and R. Laufer
High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin
Drug Metab. Dispos., October 1, 2007; 35(10): 1737 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Sudsakorn, J. Skell, D. A. Williams, T. J. O'Shea, and H. Liu
Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes
Drug Metab. Dispos., June 1, 2007; 35(6): 841 - 847.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
B.-F. Krippendorff, P. Lienau, A. Reichel, and W. Huisinga
Optimizing Classification of Drug-Drug Interaction Potential for CYP450 Isoenzyme Inhibition Assays in Early Drug Discovery
J Biomol Screen, February 1, 2007; 12(1): 92 - 99.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
M. A. Hummel, T. S. Tracy, J. M. Hutzler, J. L. Wahlstrom, Y. Zhou, and D. A. Rock
Influence of Fluorescent Probe Size and Cytochrome b5 on Drug-Drug Interactions in CYP2C9
J Biomol Screen, April 1, 2006; 11(3): 303 - 309.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Atkinson, J. R. Kenny, and K. Grime
AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS
Drug Metab. Dispos., November 1, 2005; 33(11): 1637 - 1647.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. F. McGinnity, J. Tucker, S. Trigg, and R. J. Riley
PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES
Drug Metab. Dispos., November 1, 2005; 33(11): 1700 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
R. Arimoto, M.-A. Prasad, and E. M. Gifford
Development of CYP3A4 Inhibition Models: Comparisons of Machine-Learning Techniques and Molecular Descriptors
J Biomol Screen, April 1, 2005; 10(3): 197 - 205.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Di Marco, I. Marcucci, A. Chaudhary, M. Taliani, and R. Laufer
DEVELOPMENT AND VALIDATION OF A HIGH-THROUGHPUT RADIOMETRIC CYP2C9 INHIBITION ASSAY USING TRITIATED DICLOFENAC
Drug Metab. Dispos., March 1, 2005; 33(3): 359 - 364.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. D. Marco, I. Marcucci, M. Verdirame, J. Perez, M. Sanchez, F. Pelaez, A. Chaudhary, and R. Laufer
DEVELOPMENT AND VALIDATION OF A HIGH-THROUGHPUT RADIOMETRIC CYP3A4/5 INHIBITION ASSAY USING TRITIATED TESTOSTERONE
Drug Metab. Dispos., March 1, 2005; 33(3): 349 - 358.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
O. V. Trubetskoy, J. R. Gibson, and B. D. Marks
Highly Miniaturized Formats for In Vitro Drug Metabolism Assays Using Vivid(R) Fluorescent Substrates and Recombinant Human Cytochrome P450 Enzymes
J Biomol Screen, February 1, 2005; 10(1): 56 - 66.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
B. D. Marks, D. V. Thompson, T. A. Goossens, and O. V. Trubetskoy
High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid(R) Substrates
J Biomol Screen, August 1, 2004; 9(5): 439 - 449.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. T. Donato, N. Jimenez, J. V. Castell, and M. J. Gomez-Lechon
FLUORESCENCE-BASED ASSAYS FOR SCREENING NINE CYTOCHROME P450 (P450) ACTIVITIES IN INTACT CELLS EXPRESSING INDIVIDUAL HUMAN P450 ENZYMES
Drug Metab. Dispos., July 1, 2004; 32(7): 699 - 706.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. L. Walsky and R. S. Obach
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.